PMLiVE1d
Briggids Limited
Briggids is a dynamic, global organisation with extensive experience in systematic reviews, health technology assessments, therapeutic value propositions/market access, landscape mapping and medical ...
PMLiVE7d
Merck and Astellas/Pfizer’s bladder cancer combination receives MHRA approval
Keytruda (pembrolizumab) and Astellas/Pfizer’s Padcev (enfortumab vedotin) have been approved by the Medicines and Healthcare ...
PMLiVE7d
Roche’s Itovebi combination granted FDA approval for advanced breast cancer
Roche’s PI3K inhibitor Itovebi (inavolisib) has been approved by the US Food and Drug Administration (FDA) as part of a ...
PMLiVE8d
GSK’s RSV vaccine Arexvy shown to protect older adults across three seasons
GSK’s Arexvy has been shown to protect older adults against respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD) over three full RSV seasons. Results from the phase 3 ...
PMLiVE8d
PM Society Awards 2025 open for entries
You can now start working on your entries and don’t forget to get them to us by Thursday 14 November by midnight to qualify for our early bird pricing. Entry deadline is Thursday 21 November and a ...
PMLiVE9d
PMLiVE’s T40 – results announced!
The 2024 edition of PMLiVE’s T40 list of creative agencies working on advertising, branding, creative and design projects in the UK healthcare sector has been published. The fifth edition of the list ...
PMLiVE10d
ICR researchers reveal benefits of personalised radiotherapy for bladder cancer patients
Researchers from the Institute of Cancer Research (ICR) have highlighted the potential benefits of treating bladder cancer with personalised radiotherapy. More than 130,000 patients are treated on the ...
PMLiVE11d
AbbVie shares promising late-stage results for Parkinson’s disease candidate tavapadon
AbbVie has shared positive top-line results from a late-stage study of its investigational Parkinson’s disease (PD) drug in adults. The phase 3 TEMPO-1 trial evaluated two fixed doses of the D1/D5 ...
PMLiVE14d
Researchers develop new approach to target cells affected by motor neurone disease
It is hoped that preventing healthy cells from reading the molecules’ messages could lead to safer and more effective gene therapies for MND, as well as other neurodegenerative diseases, including ...
PMLiVE14d
Chiesi Group invests €400m to establish biotech centre of excellence in Italy
Chiesi Group has announced the operational launch of its biotech centre of excellence in Italy. The company has invested €400m to establish the facility, which it said is dedicated to developing and ...
PMLiVE15d
Results from Global Pharmaceutical Customer Experience survey
Research on the state of the customer experience (CX) that the global pharmaceutical industry provides to healthcare professionals (HCPs) has been released by DT Consulting, an Indegene company. For ...